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Abstract Concentrations of cell-free DNA (cfDNA) circulat-
ing in blood and its epigenetic variation, such as DNA meth-
ylation, may provide useful diagnostic or prognostic informa-
tion. Long interspersed nuclear element-1 (LINE-1) consti-
tutes approximately 20% of the human genome and its
5’UTR region is CpG rich. Due to its wide distribution, the
methylation level of the 5’UTR of LINE-1 can serve as a
surrogate marker of global genomic DNA methylation. The
aim of the current study was to investigate whether the meth-
ylation status of LINE-1 elements in serum cell-free DNA
differs between relapsing remitting multiple sclerosis
(RRMS) patients and healthy control subjects (CTR). Serum
DNA samples of 6 patients and 6 controls were subjected to
bisulfite sequencing. The results showed that the methylation
level varies among distinct CpG sites in the 5’UTR of LINE-1
repeats and revealed differences in the methylation state of
specific sites in this element between patients and controls.
The latter differences were largely due to CpG sites in the
L1PA2 subfamily, which were more frequently methylated
in the RRMS patients than in the CTR group, whereas such
differences were not observed in the L1HS subfamily. These
data were verified by quantitative PCR using material from 18
patients and 18 control subjects. The results confirmed that the
methylation level of a subset of the CpG sites within the
LINE-1 promoter is elevated in DNA from RRMS patients
in comparison with CTR. The present data suggest that the
methylation status of CpG sites of LINE repeats could be a
basis for development of diagnostic or prognostic tests.
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Introduction
Multiple sclerosis (MS) is an autoimmune disease of the cen-
tral nervous system, for which the pathogenic mechanisms are
only poorly understood. There are several clinical courses of
MS, including relapsing remitting (RRMS), primary progres-
sive (PPMS), secondary progressive (SPMS), and progressive
relapsing (PRMS) MS [1]. RRMS is characterized by unpre-
dictable relapses followed by periods without symptoms of
disease activity (remission) and often begins with a clinically
isolated syndrome (CIS) episode. MS is difficult to diagnose
at early stages, as the MS signs and symptoms can be similar
to those of other diseases. Currently, the process of diagnosing
MS is lengthy and costly. Therefore, there is an urgent need
for highly sensitive and specific diagnostic and prognostic
tests, which are preferably minimally invasive. The identifica-
tion of biomarkers may facilitate the development of such
tests.
Cell-free DNA (cfDNA) has been detected in body fluids
such as serum and plasma. Changes in the levels or fragmen-
tation patterns of circulating cfDNA have been associated
with various diseases, in particular cancer [2]. Moreover, sev-
eral studies have reported that the analysis of cfDNA methyl-
ation can be useful for the early detection, diagnosis, and
prognosis of different diseases [3]. In the human genome,
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DNA methylation occurs predominantly at CpG dinucleo-
tides. Some CpG dinucleotides are clustered in CpG islands
(CGIs). Approximately 70% of the annotated gene promoters
are associated with CGIs, and the methylation of these
promoter-associated CGIs is associated with transcriptional
repression. Besides gene promoters, repetitive elements such
as long and short interspersed nuclear elements (LINEs and
SINEs) and tandem array repeats (satellite elements) contain a
substantial number of CGIs. These elements comprise about
45% of the human genome and are heavily methylated in
postnatal tissues to prevent their transcription [4, 5], whereas
they are frequently hypomethylated in human malignancies
[6–8].
LINEs are abundant, non-long terminal repeat (non-LTR)
retrotransposons, which are widely but unevenly distributed in
the mammalian genomes. LINE families contribute to 12% of
CpG dinucleotides in the human genome [9]. The human ge-
nome contains two superfamilies of LINEs, active LINE-1
elements and extinct families of LINE-2 and LINE-3 elements
[10]. Over 500,000 copies of LINE-1 are present in the human
genome, of which the vast majority is 5′ truncated [11]; about
3,000copies are full length and 80–100 of these are active
re t ro t ransposons [12] . Ful l - length 6-kb LINE-1
retrotransposons consist of four regions: the 5′ untranslated
region (UTR), which contains both sense and antisense pro-
moters, two open reading frames: ORF1 and ORF2, which
encode an RNA binding protein and a protein with reverse
transcriptase and endonuclease activity, respectively, and a
3’UTR containing a polyadenylation signal (Supplementary
Fig. S1) [13, 14]. A sense promoter is responsible for tran-
scription of the LINE-1 repeats and an antisense promoter
drives transcription of adjacent regions. Many LINE-1 ele-
ments show 5′ truncations and, as a consequence, are not able
to propagate due to the lack of a promoter and transcription
factor binding sites [15]. Both intact ORFs are also required
for LINE-1 retrotransposition [16]. DNA hypermethylation in
the LINE-1 promoter is important for transcriptional repres-
sion and for the inhibition of retrotransposition.
Alteration of the LINE-1 methylation status has been ob-
served for a number of cancers [17–19], rheumatoid arthritis
[20–22], and systemic lupus erythematosus [22–24]. Several
studies on the pathogenesis of autoimmune diseases suggest
that changes of DNAmethylation at the interspersed repetitive
sequences can occur under various conditions. Lymphocytes
and neutrophils from patients with SLE exhibit hypomethyla-
tion of LINE-1 [24]. A similar pattern of hypomethylation of
LINE-1 repeats in CD4+, CD8+ T cells and B lymphocytes
subsets from SLE patients in comparison with healthy con-
trols was observed [23]. A recent study on methylation of
repetitive elements demonstrated hypermethylation of repeti-
tive elements (Alu, LINE-1, and SAT-a) in whole blood ofMS
patients compared to healthy controls [25]. Methylation levels
of LINE-1 and Alu were correlated with EDSS scores.
We have previously demonstrated that there is no differ-
ence in cfDNA levels between patients with RRMS and
healthy controls [26]. The aim of the present study was to
investigate whether LINE-1 methylation levels in circulating
cfDNA are altered in RRMS. We have analyzed the methyla-
tion status of individual CpGs in LINE-1 repetitive elements
in cfDNA isolated from serum of patients with RRMS and
healthy subjects using bisulfite sequencing. The observed dif-
ferences in LINE-1 cfDNA methylation were verified by
quantitative PCR analysis of independent randomly selected
samples of RRMS patients.
Materials and Methods
Patient Samples
The RRMS patient serum samples were collected at the
Multiple Sclerosis Center (Nijmegen, The Netherlands) with-
in the 2001–2015 time frame. Serum samples from healthy
individuals were collected at the Sanquin Blood Bank
(Nijmegen, The Netherlands) or at the Radboud University
Medical Center (Nijmegen, The Netherlands). A cohort of
24 untreated RRMS patients in clinical remission was includ-
ed in this study (Table 1); patients met the following inclusion
criteria: (i) age greater than 18 years old; (ii) diagnosis of MS
according to the McDonald criteria [27]. Patients diagnosed
also with an autoimmune disorder other thanMSwere exclud-
ed from the study. Sera of 24 healthy individuals were used as
controls (CTR; Table 1). Patient sera were collected in accor-
dance with the code of conduct of research with human mate-
rial in the Netherlands. Donors provided written informed
consent. The serum samples were prepared according to stan-
dard protocols. After collection of the whole blood, the sam-
ples were left at room temperature for 1 h, and the clots were
removed by centrifugation at 2000×g for 10 min. Sera were
stored in aliquots at −80 °C.
DNA Isolation and Bisulfite Treatment
Circulating cfDNA was extracted from 200 μl serum using
QIAamp®DNA blood mini kit (Qiagen, Hilden, Germany) ac-
cording the manufacturer’s protocol. The isolated DNA was
modified by sodium bisulfite treatment using the EpiTect
Bisulfite kit (Qiagen, Hilden, Germany) according to the man-
ufacturer’s instructions.
LINE-1 Repeat Amplification, Cloning, and Sequencing
Six samples for each group were randomly selected for Bbisul-
fite sequencing^. Bisulfite-treated DNA served as template for
PCR-mediated amplification of a 376-bp amplicon using a set
of primers (L1F/LR; Table 2) specific for bisulfite converted
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DNA [28]. High Fidelity Taq Polymerase (Roche, Basel,
Switzerland) was used under the following conditions: 95 °C
for 10 min, followed by 30 cycles at 95 °C for 90 s, 43 °C for
60 s, and 72 °C for 120 s. The PCR products were separated by
2% agarose gel electrophoresis, purified using QIAEX II Gel
Extraction Kit (Qiagen, Hilden, Germany), cloned into the
pCR4 TOPO vector (TA cloning kit, Invitrogen, Carlsbad,
CA, USA) and sequenced. For each group 36 clones (6 per
sample) were analyzed. We pooled the data from 36 sequences
for each group to increase statistical power.
Methylation-Specific Quantitative PCR
A methylation-specific quantitative PCR (qPCR) assay was
used to detect methylation of LINE-1 CpG sites in cfDNA.
The primers were designed to specifically bind to bisulfite-
treated DNA. The primers specific for each CpG were de-
signed based on the sequencing data in such a way that the
discriminating nucleotide was positioned at or near the 3′ end
of the primer. The sequences of the primers used are listed in
Table 2. First, a LINE-1 fragment was amplified with the
CpG-free L1F/LR primer set (35 cycles). This fragment was
used as a template for qPCR analyses on a StepOnePlus qPCR
machine (software version 2.2; Applied Biosystems, UK).
qPCR reactions were performed in triplicate. Reactions were
carried out in a final volume of 10 μl containing GoTag qPCR
Master Mix (Promega, Fitchburg, Wisconsin, USA), 0.75 μM
of each primer, 0.1 μl CXR reference dye, and 1 μl template
DNA. The qPCR conditions were as follows: 95 °C for
10 min, followed by 40 cycles of 95 °C for 15 s, and 58 °C
for 60 s. Unmethylated and fully methylated bisulfite-treated
control DNA samples (EpiTect Control DNA, Qiagen,
Hilden, Germany) were used as negative (0% methylated)
and positive (100% methylated) controls, respectively. To
measure the amount of total DNA and DNA methylated at
the particular CpG site in each sample and amplification effi-
ciency, standard curves were created by plotting the quantities
of serially 10-fold diluted control 100% methylated DNA
(Qiagen, Hilden, Germany), logarithmically against the Ct
values. The primer set L1F/LR, which was designed to the
LINE-1 areas free of CpG sites, has been used as internal
control for normalization of DNA input (total DNA). Each
primer set specific for a certain CpG site yields information
on the amount of DNA methylated at the particular CpG site
(quantity of methylated DNA). The primer combination was
L10/LR for L1PA2-10, L18/LR for L1PA2-18, L24/LR for
L1PA2-24, and L1F1/L27 for L1PA2-27, respectively. The
relative methylation level for each Bset of primers^ was calcu-
lated according to the following formula: percentage of meth-
ylated DNA = (quantity of methylated DNA /quantity of total
DNA) × 100.
Data Analysis
High-scoring segment pair (HSP) distribution on genome was
performed with the BLAT tools [29]. To quantify and compare
the percentage of methylated CpG in both groups, the quanti-
fication tool for methylation analysis (QUMA) software was
Table 2 Primers used for
bisulfite sequencing and qPCR
analysis








The CpG positions are indicated for L1PA2 subfamily. The bold letters indicate CpG positions. L1F/LR set was
used for sequencing. The primer combination was L10/LR for L1PA2-10, L18/LR for L1PA2-18, L24/LR for
L1PA2-24, and L1F1/L27 for L1PA2-27, respectively
Table 1 Characteristics of the
patients with relapsing remitting




analysis (n = 6)
CTR samples
used for qPCR
analysis (n = 18)
RRMS samples
used for sequencing
analysis (n = 6)
RRMS samples
used for qPCR
analysis (n = 18)
Gender (male/female) 1/5 4/14 3/3 4/14
Age (years) 49.5 ± 6.0 47.5 ± 13.2 45.5 ± 5.4 43.5 ± 7.6
EDSS NA NA 2.8 ± 1.3 2.5 ± 1.7
Disease onset (years) NA NA 37.0 ± 4.3 33.5 ± 9.0
EDSS expanded disability status scale, NA not applicable
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used [30]. In order to accurately determine the percentage of
methylated LINE-1 using the qPCR assay, two different anal-
ysis methods were applied: a comparative quantification
method based on quantification cycle (Cq) and the standard
curve (SC), and the LinRegPCR method [31]. The compara-
tivemethod relies on the assumption that the PCR efficiency is
constant for the target and the reference amplicons. However,
it has been shown that PCR efficiencies for target and refer-
ence amplicons often vary and this difference can lead to
under- or overestimation of the target quantity. The
LinRegPCRmethod allows the calculation of starting material
and PCR efficiency for each individual sample.
A standard curve was generated by performing qPCRwith a
serial dilution of fully methylated DNA and was used to calcu-
late the concentration of the cfDNA in the samples. The Ct
values were plotted versus the log of the dilution. The efficiency
was calculated based on the slope of the standard curve. The
LinRegPCR method calculates efficiencies for each individual
sample and uses the mean PCR efficiency per amplicon and the
Ct value per sample to calculate the starting concentration per
sample.
Statistical Analysis
Statistical analysis was performed using SPSS 21.0 software
(IBM SPSS Statistics for Windows, Version 21.0, Armonk,
NY, USA). QUMA software performs a statistical analysis
between the methylation profiles. Fisher’s exact test and the
Mann-Whitney U test were used to determine the statistical
significance of the difference for two groups at each CpG site
or for the entire sets of CpG sites. All p values shown are for
two-tailed tests with p < 0.05 considered significant.
Results
Patients and Controls
Two groups, each consisting of 24 subjects, were included in
this study, RRMS patients in clinical remission and healthy
controls (CTR). Characteristics of the study participants are
summarized in Table 1. There were no significant differences
in age and gender between the groups. The average age for the
CTR and RRMS was 49 ± 14 and 46 ± 7 years, respectively,
and the percentage of female subjects in both groups was high
(85 versus 92%, respectively). Circulating cfDNAwas isolat-
ed from serum samples of each of these subjects.
Methylation Analysis of LINE-1 cfDNA Using Bisulfite
Sequencing
To obtain information on the methylation state of individual
CpG sites in the 5’UTR of LINE-1 in circulating cfDNA, the
corresponding fragments were amplified by PCR (L1F/LR
primer set) and cloned in the pCR4-TOPO vector. Thirty-six
clones derived from 6 randomly selected RRMS subjects and
36 clones derived from 6 healthy subjects were sequenced (six
clones per subject). In view of the copy number of full-length
LINE-1 elements in the human genome,most, if not all, of these
clones were expected to be derived from distinct LINE-1 ele-
ments. With the help of the software tool CENSOR [32], which
screens a reference collection of repeats with a query, three
LINE-1 subfamilies, L1PA2, L1Pt-5 end, and L1HS (human-
specific L1, currently active gene in human genome) were iden-
tified. Of the CTR and RRMS sequences 41% and 32%, re-
spectively, corresponded to L1HS, while the majority of the
remaining sequences represented L1PA2 elements. Only two
L1Pt-5 elements were found, both in CTR samples. The obtain-
ed sequences for L1PA2 and L1HS differed at several CpG
positions (Fig. 1).
Methylation analysis was performed using the QUMA
software. L1PA2 and L1HS showed the presence of 27 and
25 CpG sites, respectively (Fig. 1), 19 of which are shared by
both subfamilies. The mean methylation level for the com-
bined 27 sites of RRMS L1PA2 (50 ± 18%) was higher than
that of CTR L1PA2 (40 ± 22%; p = 0.019). No differences
between the mean methylation level for the combined 25 sites
of RRMS L1HS (84 ± 11%) and CTR L1HS (84 ± 15%;
p = 0.41) were observed.
We next examined the methylation level at individual
LINE-1 CpG sites in cfDNA. The methylation level varied
Fig. 1 Sequence alignment of CpG islands of the L1PA2 and L1HS
subfamilies. The positions of each CpG site are indicated in red. The
L1PA2 and L1HS subfamily contain 27 and 25 CpG sites, respectively
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considerably among individual CpG sites, ranging from 0 to
67% for CTR and from 0 to 78% for RRMS L1PA2 and
ranging from 36 to 100% for CTR and from 60 to 100% for
RRMS L1HS (Fig. 2). Three individual CpG sites (L1PA2
sites 10, 11, and 18) showed significantly higher methylation
levels in the RRMS group compared with CTR (p < 0.05, Fig.
2). L1PA2 CpG site 20 displayed significantly lower methyl-
ation levels in RRMS compared with CTR (p = 0.04). CpG
sites 24 and 27 in L1PA2 and CpG site 25 in L1HS showed
higher methylation levels in RRMS patients compared to
CTR, but the differences did not reach significance (p = 0.08
and p = 0.09, and p = 0.09, respectively). No significant dif-
ferences between CTR and RRMS were observed for other
individual CpG sites of L1HS (Fig. 2).
Methylation Analysis of Individual LINE-1 CpG Sites
by qPCR
To verify the methylation status of individual CpG sites,
which were selected based upon the data described above,
a CpG methylation-specific qPCR assay was developed
and used to analyze cfDNA from distinct RRMS patients
(n = 18) and control subjects (n = 18). These analyses were
focused on L1PA2 CpG sites 10, 18, 24, and 27. Primer set
L1F/LR, which is complementary to LINE-1 areas free of
CpG sites, was used as internal reference for normalization
of DNA input. The primers specific for each CpG site stud-
ied were designed based on the sequencing data in such a
way that the discriminating nucleotide was positioned at or
near the 3′ end of the primer. It is well known that mis-
matches located in the 3′ end region of the primer are det-
rimental for PCR amplification and have significantly
larger effects on priming efficiency than more 5′ located
mismatches [33–35].
The specificity of the methylation-specific primers was
established by PCR using either fully methylated or
unmethylated bisulfite-treated DNA as positive and nega-
tive controls, respectively. These primers indeed resulted
in PCR products only when methylated DNA was used as
a template (Fig. 3a), confirming their specificity.
Both SC and LinRegPCRmethods were applied to evalu-
ate the methylation levels of CpG sites. The qPCR results
revealed that only CpG site 27 showed significant difference
in methylation levels between the RRMS and CTR groups
(p = 0.02, Fig. 3b). There was a trend for higher methylation
levels for CpG site 24, but it did not reach significance
(p=0.06). Therewasno significant difference inmethylation
levels for the otherCpGsites (10 and18) betweenRRMSand
CTR. Thus, the qPCR results confirmed hypermethylation at
L1PA2site27inRRMS,assuggestedbybisulfitesequencing.
Multivariate analysis of variance (MANOVA) used to study
the relationshipbetween themethylationstatusof theL1PA2-
24andL1PA2-27sitesandRRMSdemonstratedsignificantly
highermethylation levels of these two sites inRRMS in com-
parison with CTR (p = 0.02). Thus, the methylation level of
twoCpGsites assayed incombinationmight increase the sen-
sitivityof theassay. Inaddition, statistical analysishas shown
thatmethylation levels ofL1PA2CpGsites 10, 18, 24, and27
werenotcorrelatedwithage,gender,anddiseaseduration.No
correlation was observed between methylation levels of
L1PA2 CpG sites 18, 24, and 27 and Expanded Disability
Status Scale (EDSS). The methylation level of L1PA2 CpG
site 10 was significantly and negatively correlated with the
EDSS score (the correlation coefficient is−0.69, p= 0.004).
Fig. 2 L1PA2 and L1HS methylation status in cfDNA determined by
bisulfite sequencing. cfDNA was isolated from the serum of 6 healthy
controls and 6 RRMS patients. After bisulfite treatment and cloning of the
resulting DNA, 6 clones for each individual were selected and subjected
to DNA sequence analysis. The methylation analysis was performed by
Quantification Tool for Methylation Analysis (QUMA). The schemes
show the methylation levels as pie charts for each individual CpG site
in the L1PA2 subfamily and the L1HS subfamily. Open circles represent
completely unmethylated sites and filled circles represent full
methylation. The methylation level of each individual CpG site in
RRMS and CTR was compared using Fischer’s exact test. *p < 0.05.,
CpG sites show a trend for higher methylation levels but the differences
do not reach significance #p = 0.08, p = 0.09, and p = 0.08, respectively.
The numbers below each CpG site indicate the position of the respective
CpG site in the L1PA2/L1HS element
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Discussion
In the present study, we analyzed the methylation pattern of
the promoter region of LINE-1 repetitive elements in serum
cfDNA from RRMS patients and healthy individuals using
bisulfite sequencing and qPCR analysis. Two major LINE-1
subfamilies were identified in both groups, L1PA2 and L1HS.
The L1PA2 subfamily represents an ancestral lineage and was
found in the human and chimpanzee genomes [36]. The L1HS
subfamily comprises relatively Byoung^ LINE-1 elements and
is specific for humans. Overall CpG methylation levels of
L1PA2 subfamily fragments in cfDNA were significantly
higher in RRMS than in CTR (50 ± 18 vs 40 ± 22%;
p = 0.019). Higher L1PA2 methylation levels might be asso-
ciated with lower expression levels. It has been shown that
single or combinations of nucleotide differences within the
LINE-1 5’UTRs influence the promoter activity and as a con-
sequence transcriptional activity [37].
The L1HS fragments displayed higher overall methylation
levels than L1PA2 fragments. No significant differences be-
tween the mean methylation levels of RRMS L1HS and CTR
L1HS were observed (84 ± 11 vs 84 ± 15%; p = 0.41). The
high overall L1HS CpG methylation levels in both groups are
in agreement with the results of previously published studies,
which demonstrated that young retrotransposon elements are
more heavily methylated than more ancient elements, most
likely to prevent their retrotransposition within the genome
[9, 38]. Moreover, older elements also display more mutations
due to deamination and/or nucleotide substitutions. Mutations
within the LINE-1 promoter have the potential to reduce
LINE-1 retrotransposition activity [39]. Indeed, we observed
higher antisense deamination and mutation rates for the
L1PA2 subfamily in comparison with the L1HS subfamily.
No significant differences in antisense deamination and muta-
tion frequencies were detected between control individuals
and RRMS (data not shown).
We used two methods, bisulfite sequencing and qPCR with
methylation-specific primers, to measure the methylation levels
of individual CpG sites of LINE-1 repeats. Bisulfite sequencing
revealed that the methylation levels varied considerably among
individual CpG sites of LINE-1 elements and the methylation
levels of several CpG sites differed between CTR and RRMS.
L1PA2CpG sites 10, 11, 18, 20, 24, and 27 showed 1.3–3.3-fold
alterations in methylation levels. However, the analysis of a larg-
er group of samples by qPCR demonstrated a significant differ-
ence only for CpG site 27. The lack of significance for CpG sites
10, 18, and 24 might be attributed to the small sample size used
for bisulfite sequencing. Moreover, the high degree of homology
between L1PA2 and L1HS primer sets for CpG sites 10 and 24
(11 and 22, respectively, in L1HS) most likely does not allow
differentiation between the L1PA2 and L1HS sequences, and as
a consequence, the qPCR results obtained for these sites have to
Fig. 3 LINE-1 promoter CpG
site analysis by methylation-
specific quantitative PCR assay. a
Analysis of PCR products by
agarose gel electrophoresis to
check primer specificity. U
completely unmethylated DNA;
M fullymethylated DNA,NTC no
template control, DNA size
markers (base pairs) are shown on
the left. The size (base pairs) of
the amplicons is indicated on the
right. bMethylation level for
L1PA2 CpG sites 10, 18, 24, and
27 determined by qPCR using
samples from RRMS patients and
CTR. The horizontal bars
indicate the median with
interquartile range. The two
groups were compared using
unpaired Mann-Whitney tests
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be interpretedwith care. In addition, due to the close proximity of
some CpG sites, a few of these, which did not show any differ-
ence in methylation level, were present in the primers. These
factors imply that qPCR analysis may be associated with an
underestimation of methylation levels at sites 10 and 24.
Our results agree with those of recent studies on Tcells show-
ing that methylation of only a few CpG sites can be used to
discriminate RRMS patients from CTR. Two CpG sites were
hypermethylated in CD4+ and CD8+ T cells from MS patients
compared to controls; one CpG upstream of the TMEM48 gene
and another CpG in the last exon of theAPC2 gene [40]. Another
example of selective CpG site methylation differences was pro-
vided by studies of three CpG sites in blood samples, allowing
reliable age prediction [41, 42]. Moreover, hypermethylation of
CpG sites in repetitive elements (Alu, LINE-1, and SAT-a) in
whole blood from MS patients compared to healthy controls
was observed [25]. Thus, methylation patterns of cfDNA might
reflect themethylation changes in blood cells, which is consistent
with the fact that cfDNA originates from these cells.
One would expect to find a relatively large variety of circu-
lating DNA methylation patterns in different individuals due to
possible variations in cell number, cellular heterogeneity, age,
gender, enzymatic activities and technical variations in sample
preparation. In this respect, it is also important to note that it has
been demonstrated that methylation levels of LINE-1 elements
from different loci can be different [16]. All these factors could
confound the LINE-1 methylation analysis. However, the re-
sults of the current study strongly suggest that serum cfDNA
methylation might serve as a reliable surrogate marker for mul-
tiple sclerosis, provided the analyses are performed in a system-
atic manner. To explore its applicability, samples from larger
and independently collected cohorts, and cohorts of other sub-
types of MS, need to be analyzed. In addition, data on samples
from early MS and pre-disease patients will be required to
assess its predictive value.
The assessment of global DNA methylation is often per-
formed via the analysis of the methylation status of repetitive
elements [43–46]. However, in general the number of CpG sites
assessed is rather small (2 to 4 CpG sites), especially when
methylation is analyzed by restriction enzyme analysis (com-
bined bisulfite restriction analysis; COBRA). Our results indi-
cate that the results of LINE-1CpGmethylation to assess global
methylation should be interpreted with care due to the relatively
large differences in the methylation levels of individual sites.
In summary, the results of this study indicate that the analysis
of overall LINE-1methylation levels in serum cfDNA to discrim-
inate RRMS patients from CTR is feasible for the L1PA2 sub-
family. In addition, our results suggest that the methylation status
of specific CpG sites may provide a basis for a molecular marker
for RRMS: a significant increase in methylation of L1PA2 CpG
site 27 was observed in circulating cfDNA of RRMS patients.
Thus, the methylation status of circulating cfDNA may reflect
pathophysiological phenomena in the brain. More extensive
studies are needed to further characterize the association of the
methylation status of cfDNA and multiple sclerosis.
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